[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100512316":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":25,"centralContacts":30,"locations":36,"responsibleParty":63,"collaborators":20,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":20,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":20,"enrollmentInfo":75,"targetDuration":20,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":20,"overallStatus":39,"whyStopped":20,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Universitair Ziekenhuis Brussel","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"1 arm including patients with CAP and\u002For SFN","1 arm including patients with chronic axonal length-dependent polyneuropathy and\u002For small-fiber neuropathy.\n\nAll participants will be screened with ECG and echocardiography. All participants will be asked to complete questionnaires about there polyneuropathy and cardiological symptoms.",[12,13],"Diagnostic Test: ECG + echocardiography","Other: Answering questionnaires",[15,21],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIAGNOSTIC_TEST","ECG + echocardiography","Electrocardiogram and echocardiography",[9],null,{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":20},"Answering questionnaires","Answering questionnaires about polyneuropathy symptoms (NTSS -6, COMPASS31, NIS, mPND) and also cardialogical symptoms (KCCQ-12).",[9],[26],{"name":27,"affiliation":28,"role":29},"Veronique Bissay, MD, Phd","UZ Brussel - VUB","PRINCIPAL_INVESTIGATOR",[31],{"name":32,"role":33,"phone":34,"phoneExt":20,"email":35},"Véronique Bissay, MD,Phd","CONTACT","+32 2 477 68 01","veronique.bissay@uzbrussel.be",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"UZ Brussel","RECRUITING","Jette","Belgium Capital City","1090","Belgium","BE",{"type":46,"coordinates":47},"Point",[48,49],4.33419,50.87309,{"lat":49,"lon":48},[52,54,58,60],{"name":53,"role":33,"phone":34,"phoneExt":20,"email":35},"Veronique Bissay, MD, PhD",{"name":55,"role":33,"phone":56,"phoneExt":20,"email":57},"Steven Droogmans, MD, PhD","+32 2 477 60 09","steven.droogmans@uzbrussel.be",{"name":59,"role":29,"phone":20,"phoneExt":20,"email":20},"Véronique Bissay, MD, Phd",{"name":61,"role":62,"phone":20,"phoneExt":20,"email":20},"Steven Droogmans, MD, Phd","SUB_INVESTIGATOR",{"type":29,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Veronique Bissay","Principal Investigator","100512316","prevalence-of-wild-type-ttr-cardiac-amyloidosis-in-patients-with-polyneuropathy-of-unknown-cause-100512316",false,"NCT05950867","Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause.","Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause: a Prospective Monocentric Study (CAP-TTR)","Inclusion Criteria:\n\n* Patients with chronic axonal length-dependent polyneuropathy (CAP) and\u002For small-fiber neuropathy (SFN) without well-defined etiology.\n* Age: \\>= 60 years\n* Male and female gender\n* Written informed consent\n\nExclusion Criteria:\n\n* Known cause of polyneuropathy\n* Other types of peripheral neuropathy than chronic axonal length-dependent polyneuropathy (CAP) and\u002For small-fiber neuropathy (SFN).\n* Patients younger than 60 years","ALL","60 Years",{"count":76,"type":77},150,"ESTIMATED","INTERVENTIONAL",[80],"NA","To investigate to what extent chronic axonal length-dependent polyneuropathy (CAP) and\u002For small-fiber neuropathy (SFN) is part of early non-cardiac manifestations of wild-type TTR cardiac amyloidosis (wtTTR-CA).\n\nConsequently, explore whether this could ultimately lead to faster diagnosis and clinical outcome of wild-type TTR cardiac amyloidosis (wtTTR-CA).",[83,84],"Polyneuropathy","Amyloidosis","2025-07-17",{"date":87,"type":88},"2025-07-22","ACTUAL",{"date":90,"type":88},"2023-07-28",{"date":92,"type":77},"2026-06-01",{"name":5,"class":6},1]